Lumida
/OSCR
⌘K
Oscar Health Inc

Oscar Health Inc

OSCR
$32.77USD+0.58%+0.19 today

MARKET CAP

9.9B

P/E (TTM)

FWD P/E

DAY RANGE

$33 – $34

52W RANGE

$11
$34

AI Summary

Stalk
StalkMedium

OSCR is in a Stage 2 advance confirmed by a recent momentum breakout, but price is currently consolidating just above the rising 9/20 EMAs and horizontal breakout zone in overbought territory. Medium-term bias remains bullish on rising EMAs and structural breakout, yet short-term timing is unclear until a defined pullback or continuation signal emerges. Preferred engagement is deferred, stalking for pullbacks into the confluence of the 9EMA/20EMA or prior resistance as support.

  • Q2 revenue $4.9B (+70% YoY); H1 net income $1B.
  • Membership grows 46% to 2.96M, boosting ACA market share.
  • Insider sales drove 3.8% share drop; flagged 31.7% overvaluation.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.8B$3.9B$5.7B$9.0B$11.5B
YoY %+114.3%+45.0%+57.5%+27.9%
P / Sales0.8x0.1x0.4x0.4x0.3x
EV / Sales1.2x0.7x0.5x0.7x0.6x
Gross Profit, Adj.$212.4M$655.2M$1.1B$1.7B$1.5B
YoY %+208.5%+62.6%+55.7%-10.8%
Margin %11.6%16.6%18.7%18.5%12.9%
EV / Gross Profit10.5x4.0x2.8x3.5x4.3x
EBITDA, Adj.$-448.4M$-602.2M$-360.4M$-96.3M$-570.4M
YoY %-34.3%+40.2%+73.3%-492.2%
Margin %-24.4%-15.3%-6.3%-1.1%-5.0%
EV / EBITDA-5.0x-4.3x-8.2x-60.9x-11.1x
EBIT$-602.1M$-617.5M$-391.1M$-128.5M$-599.3M
YoY %-2.6%+36.7%+67.1%-366.5%
Margin %-32.8%-15.7%-6.9%-1.4%-5.2%
EV / EBIT-3.7x-4.2x-7.5x-45.7x-10.6x
Net Income$-572.6M$-606.3M$-270.7M$25.4M$-443.2M
YoY %-5.9%+55.3%+109.4%-1842.5%
Net Margin-31.2%-15.4%-4.7%0.3%-3.9%
EPS (GAAP)-$3.20-$2.85-$1.22$0.10-$1.69
YoY %+10.9%+57.2%+108.2%-1790.0%